Industry Research Reports
Home > Reports > Service & Software > Global Virtual Screening for Drug Discovery Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Virtual Screening for Drug Discovery Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Service & Software
Published Date: 2025-08-05
Pages: 156 Pages
Report ld: 4899801
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
The global Virtual Screening for Drug Discovery market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Virtual screening (VS) is a computational technique used in drug discovery to search libraries of small molecules in order to identify those structures which are most likely to bind to a drug target, typically a protein receptor or enzyme.
From a downstream perspective, Pharmaceutical Company accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Virtual Screening for Drug Discovery leading manufacturers including MedChemExpress, TargetMol, OpenEye Scientific, Eurofins Discovery, Sygnature Discovery, Jubilant Biosys, Schrödinger, Inc., Cresset Group, ComputaBio, Profacgen, etc., dominate supply; the top five capture approximately % of global revenue, with MedChemExpress leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Virtual Screening for Drug Discovery market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- MedChemExpress
- TargetMol
- OpenEye Scientific
- Eurofins Discovery
- Sygnature Discovery
- Jubilant Biosys
- Schrödinger, Inc.
- Cresset Group
- ComputaBio
- Profacgen
- CD ComputaBio
- Creative Biolabs
- BOC Sciences
- CKTTDB
- HitGen
- WuXi AppTec
- LeadBuilder
- CSNpharm
- ChemNavigator
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Structure-based Virtual Screening (SBVS)
- Ligand-based Virtual Screening (LBVS)
- Hybrid Methods
Segment by Application
- Pharmaceutical Company
- Universities and Research Institutions
- Others
CHAPTER OUTLINE
Chapter 1: Defines the Virtual Screening for Drug Discovery study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Virtual Screening for Drug Discovery: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Virtual Screening for Drug Discovery Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Structure-based Virtual Screening (SBVS)
1.2.3 Ligand-based Virtual Screening (LBVS)
1.2.4 Hybrid Methods
1.3 Market Segmentation by Application
1.3.1 Global Virtual Screening for Drug Discovery Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Company
1.3.3 Universities and Research Institutions
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Virtual Screening for Drug Discovery Revenue Estimates and Forecasts 2020-2031
2.2 Global Virtual Screening for Drug Discovery Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Virtual Screening for Drug Discovery Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Virtual Screening for Drug Discovery Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Structure-based Virtual Screening (SBVS) Market Size by Players
3.3.2 Ligand-based Virtual Screening (LBVS) Market Size by Players
3.3.3 Hybrid Methods Market Size by Players
3.4 Global Virtual Screening for Drug Discovery Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Virtual Screening for Drug Discovery Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Virtual Screening for Drug Discovery Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Virtual Screening for Drug Discovery Market Size by Type (2020-2031)
6.4 North America Virtual Screening for Drug Discovery Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Virtual Screening for Drug Discovery Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Virtual Screening for Drug Discovery Market Size by Type (2020-2031)
7.4 Europe Virtual Screening for Drug Discovery Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Virtual Screening for Drug Discovery Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Virtual Screening for Drug Discovery Market Size by Type (2020-2031)
8.4 Asia-Pacific Virtual Screening for Drug Discovery Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Virtual Screening for Drug Discovery Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Virtual Screening for Drug Discovery Market Size by Type (2020-2031)
9.4 Central and South America Virtual Screening for Drug Discovery Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Virtual Screening for Drug Discovery Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Virtual Screening for Drug Discovery Market Size by Type (2020-2031)
10.4 Middle East and Africa Virtual Screening for Drug Discovery Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Virtual Screening for Drug Discovery Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 MedChemExpress
11.1.1 MedChemExpress Corporation Information
11.1.2 MedChemExpress Business Overview
11.1.3 MedChemExpress Virtual Screening for Drug Discovery Product Features and Attributes
11.1.4 MedChemExpress Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.1.5 MedChemExpress Virtual Screening for Drug Discovery Revenue by Product in 2024
11.1.6 MedChemExpress Virtual Screening for Drug Discovery Revenue by Application in 2024
11.1.7 MedChemExpress Virtual Screening for Drug Discovery Revenue by Geographic Area in 2024
11.1.8 MedChemExpress Virtual Screening for Drug Discovery SWOT Analysis
11.1.9 MedChemExpress Recent Developments
11.2 TargetMol
11.2.1 TargetMol Corporation Information
11.2.2 TargetMol Business Overview
11.2.3 TargetMol Virtual Screening for Drug Discovery Product Features and Attributes
11.2.4 TargetMol Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.2.5 TargetMol Virtual Screening for Drug Discovery Revenue by Product in 2024
11.2.6 TargetMol Virtual Screening for Drug Discovery Revenue by Application in 2024
11.2.7 TargetMol Virtual Screening for Drug Discovery Revenue by Geographic Area in 2024
11.2.8 TargetMol Virtual Screening for Drug Discovery SWOT Analysis
11.2.9 TargetMol Recent Developments
11.3 OpenEye Scientific
11.3.1 OpenEye Scientific Corporation Information
11.3.2 OpenEye Scientific Business Overview
11.3.3 OpenEye Scientific Virtual Screening for Drug Discovery Product Features and Attributes
11.3.4 OpenEye Scientific Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.3.5 OpenEye Scientific Virtual Screening for Drug Discovery Revenue by Product in 2024
11.3.6 OpenEye Scientific Virtual Screening for Drug Discovery Revenue by Application in 2024
11.3.7 OpenEye Scientific Virtual Screening for Drug Discovery Revenue by Geographic Area in 2024
11.3.8 OpenEye Scientific Virtual Screening for Drug Discovery SWOT Analysis
11.3.9 OpenEye Scientific Recent Developments
11.4 Eurofins Discovery
11.4.1 Eurofins Discovery Corporation Information
11.4.2 Eurofins Discovery Business Overview
11.4.3 Eurofins Discovery Virtual Screening for Drug Discovery Product Features and Attributes
11.4.4 Eurofins Discovery Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.4.5 Eurofins Discovery Virtual Screening for Drug Discovery Revenue by Product in 2024
11.4.6 Eurofins Discovery Virtual Screening for Drug Discovery Revenue by Application in 2024
11.4.7 Eurofins Discovery Virtual Screening for Drug Discovery Revenue by Geographic Area in 2024
11.4.8 Eurofins Discovery Virtual Screening for Drug Discovery SWOT Analysis
11.4.9 Eurofins Discovery Recent Developments
11.5 Sygnature Discovery
11.5.1 Sygnature Discovery Corporation Information
11.5.2 Sygnature Discovery Business Overview
11.5.3 Sygnature Discovery Virtual Screening for Drug Discovery Product Features and Attributes
11.5.4 Sygnature Discovery Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.5.5 Sygnature Discovery Virtual Screening for Drug Discovery Revenue by Product in 2024
11.5.6 Sygnature Discovery Virtual Screening for Drug Discovery Revenue by Application in 2024
11.5.7 Sygnature Discovery Virtual Screening for Drug Discovery Revenue by Geographic Area in 2024
11.5.8 Sygnature Discovery Virtual Screening for Drug Discovery SWOT Analysis
11.5.9 Sygnature Discovery Recent Developments
11.6 Jubilant Biosys
11.6.1 Jubilant Biosys Corporation Information
11.6.2 Jubilant Biosys Business Overview
11.6.3 Jubilant Biosys Virtual Screening for Drug Discovery Product Features and Attributes
11.6.4 Jubilant Biosys Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.6.5 Jubilant Biosys Recent Developments
11.7 Schrödinger, Inc.
11.7.1 Schrödinger, Inc. Corporation Information
11.7.2 Schrödinger, Inc. Business Overview
11.7.3 Schrödinger, Inc. Virtual Screening for Drug Discovery Product Features and Attributes
11.7.4 Schrödinger, Inc. Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.7.5 Schrödinger, Inc. Recent Developments
11.8 Cresset Group
11.8.1 Cresset Group Corporation Information
11.8.2 Cresset Group Business Overview
11.8.3 Cresset Group Virtual Screening for Drug Discovery Product Features and Attributes
11.8.4 Cresset Group Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.8.5 Cresset Group Recent Developments
11.9 ComputaBio
11.9.1 ComputaBio Corporation Information
11.9.2 ComputaBio Business Overview
11.9.3 ComputaBio Virtual Screening for Drug Discovery Product Features and Attributes
11.9.4 ComputaBio Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.9.5 ComputaBio Recent Developments
11.10 Profacgen
11.10.1 Profacgen Corporation Information
11.10.2 Profacgen Business Overview
11.10.3 Profacgen Virtual Screening for Drug Discovery Product Features and Attributes
11.10.4 Profacgen Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 CD ComputaBio
11.11.1 CD ComputaBio Corporation Information
11.11.2 CD ComputaBio Business Overview
11.11.3 CD ComputaBio Virtual Screening for Drug Discovery Product Features and Attributes
11.11.4 CD ComputaBio Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.11.5 CD ComputaBio Recent Developments
11.12 Creative Biolabs
11.12.1 Creative Biolabs Corporation Information
11.12.2 Creative Biolabs Business Overview
11.12.3 Creative Biolabs Virtual Screening for Drug Discovery Product Features and Attributes
11.12.4 Creative Biolabs Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.12.5 Creative Biolabs Recent Developments
11.13 BOC Sciences
11.13.1 BOC Sciences Corporation Information
11.13.2 BOC Sciences Business Overview
11.13.3 BOC Sciences Virtual Screening for Drug Discovery Product Features and Attributes
11.13.4 BOC Sciences Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.13.5 BOC Sciences Recent Developments
11.14 CKTTDB
11.14.1 CKTTDB Corporation Information
11.14.2 CKTTDB Business Overview
11.14.3 CKTTDB Virtual Screening for Drug Discovery Product Features and Attributes
11.14.4 CKTTDB Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.14.5 CKTTDB Recent Developments
11.15 HitGen
11.15.1 HitGen Corporation Information
11.15.2 HitGen Business Overview
11.15.3 HitGen Virtual Screening for Drug Discovery Product Features and Attributes
11.15.4 HitGen Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.15.5 HitGen Recent Developments
11.16 WuXi AppTec
11.16.1 WuXi AppTec Corporation Information
11.16.2 WuXi AppTec Business Overview
11.16.3 WuXi AppTec Virtual Screening for Drug Discovery Product Features and Attributes
11.16.4 WuXi AppTec Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.16.5 WuXi AppTec Recent Developments
11.17 LeadBuilder
11.17.1 LeadBuilder Corporation Information
11.17.2 LeadBuilder Business Overview
11.17.3 LeadBuilder Virtual Screening for Drug Discovery Product Features and Attributes
11.17.4 LeadBuilder Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.17.5 LeadBuilder Recent Developments
11.18 CSNpharm
11.18.1 CSNpharm Corporation Information
11.18.2 CSNpharm Business Overview
11.18.3 CSNpharm Virtual Screening for Drug Discovery Product Features and Attributes
11.18.4 CSNpharm Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.18.5 CSNpharm Recent Developments
11.19 ChemNavigator
11.19.1 ChemNavigator Corporation Information
11.19.2 ChemNavigator Business Overview
11.19.3 ChemNavigator Virtual Screening for Drug Discovery Product Features and Attributes
11.19.4 ChemNavigator Virtual Screening for Drug Discovery Revenue and Gross Margin (2020-2025)
11.19.5 ChemNavigator Recent Developments
12 Virtual Screening for Drug DiscoveryIndustry Chain Analysis
12.1 Virtual Screening for Drug Discovery Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Virtual Screening for Drug Discovery Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Virtual Screening for Drug Discovery Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Virtual Screening for Drug Discovery Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Virtual Screening for Drug Discovery Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Virtual Screening for Drug Discovery Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Virtual Screening for Drug Discovery Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Virtual Screening for Drug Discovery Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Virtual Screening for Drug Discovery Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Virtual Screening for Drug Discovery Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Virtual Screening for Drug Discovery by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Virtual Screening for Drug Discovery as of 2024)
Table 11. Global Virtual Screening for Drug Discovery Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Virtual Screening for Drug Discovery Companies Headquarters
Table 13. Global Virtual Screening for Drug Discovery Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Virtual Screening for Drug Discovery Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Virtual Screening for Drug Discovery Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Virtual Screening for Drug Discovery Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Virtual Screening for Drug Discovery Revenue by Application (2026-2031) & (US$ Million)
Table 21. Virtual Screening for Drug Discovery High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Virtual Screening for Drug Discovery Growth Accelerators and Market Barriers
Table 25. North America Virtual Screening for Drug Discovery Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Virtual Screening for Drug Discovery Growth Accelerators and Market Barriers
Table 27. Europe Virtual Screening for Drug Discovery Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Virtual Screening for Drug Discovery Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Virtual Screening for Drug Discovery Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Virtual Screening for Drug Discovery Investment Opportunities and Key Challenges
Table 31. Central and South America Virtual Screening for Drug Discovery Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Virtual Screening for Drug Discovery Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Virtual Screening for Drug Discovery Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. MedChemExpress Corporation Information
Table 35. MedChemExpress Description and Major Businesses
Table 36. MedChemExpress Product Features and Attributes
Table 37. MedChemExpress Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. MedChemExpress Revenue Proportion by Product in 2024
Table 39. MedChemExpress Revenue Proportion by Application in 2024
Table 40. MedChemExpress Revenue Proportion by Geographic Area in 2024
Table 41. MedChemExpress Virtual Screening for Drug Discovery SWOT Analysis
Table 42. MedChemExpress Recent Developments
Table 43. TargetMol Corporation Information
Table 44. TargetMol Description and Major Businesses
Table 45. TargetMol Product Features and Attributes
Table 46. TargetMol Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. TargetMol Revenue Proportion by Product in 2024
Table 48. TargetMol Revenue Proportion by Application in 2024
Table 49. TargetMol Revenue Proportion by Geographic Area in 2024
Table 50. TargetMol Virtual Screening for Drug Discovery SWOT Analysis
Table 51. TargetMol Recent Developments
Table 52. OpenEye Scientific Corporation Information
Table 53. OpenEye Scientific Description and Major Businesses
Table 54. OpenEye Scientific Product Features and Attributes
Table 55. OpenEye Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. OpenEye Scientific Revenue Proportion by Product in 2024
Table 57. OpenEye Scientific Revenue Proportion by Application in 2024
Table 58. OpenEye Scientific Revenue Proportion by Geographic Area in 2024
Table 59. OpenEye Scientific Virtual Screening for Drug Discovery SWOT Analysis
Table 60. OpenEye Scientific Recent Developments
Table 61. Eurofins Discovery Corporation Information
Table 62. Eurofins Discovery Description and Major Businesses
Table 63. Eurofins Discovery Product Features and Attributes
Table 64. Eurofins Discovery Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Eurofins Discovery Revenue Proportion by Product in 2024
Table 66. Eurofins Discovery Revenue Proportion by Application in 2024
Table 67. Eurofins Discovery Revenue Proportion by Geographic Area in 2024
Table 68. Eurofins Discovery Virtual Screening for Drug Discovery SWOT Analysis
Table 69. Eurofins Discovery Recent Developments
Table 70. Sygnature Discovery Corporation Information
Table 71. Sygnature Discovery Description and Major Businesses
Table 72. Sygnature Discovery Product Features and Attributes
Table 73. Sygnature Discovery Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Sygnature Discovery Revenue Proportion by Product in 2024
Table 75. Sygnature Discovery Revenue Proportion by Application in 2024
Table 76. Sygnature Discovery Revenue Proportion by Geographic Area in 2024
Table 77. Sygnature Discovery Virtual Screening for Drug Discovery SWOT Analysis
Table 78. Sygnature Discovery Recent Developments
Table 79. Jubilant Biosys Corporation Information
Table 80. Jubilant Biosys Description and Major Businesses
Table 81. Jubilant Biosys Product Features and Attributes
Table 82. Jubilant Biosys Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Jubilant Biosys Recent Developments
Table 84. Schrödinger, Inc. Corporation Information
Table 85. Schrödinger, Inc. Description and Major Businesses
Table 86. Schrödinger, Inc. Product Features and Attributes
Table 87. Schrödinger, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Schrödinger, Inc. Recent Developments
Table 89. Cresset Group Corporation Information
Table 90. Cresset Group Description and Major Businesses
Table 91. Cresset Group Product Features and Attributes
Table 92. Cresset Group Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Cresset Group Recent Developments
Table 94. ComputaBio Corporation Information
Table 95. ComputaBio Description and Major Businesses
Table 96. ComputaBio Product Features and Attributes
Table 97. ComputaBio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. ComputaBio Recent Developments
Table 99. Profacgen Corporation Information
Table 100. Profacgen Description and Major Businesses
Table 101. Profacgen Product Features and Attributes
Table 102. Profacgen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Profacgen Recent Developments
Table 104. CD ComputaBio Corporation Information
Table 105. CD ComputaBio Description and Major Businesses
Table 106. CD ComputaBio Product Features and Attributes
Table 107. CD ComputaBio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. CD ComputaBio Recent Developments
Table 109. Creative Biolabs Corporation Information
Table 110. Creative Biolabs Description and Major Businesses
Table 111. Creative Biolabs Product Features and Attributes
Table 112. Creative Biolabs Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Creative Biolabs Recent Developments
Table 114. BOC Sciences Corporation Information
Table 115. BOC Sciences Description and Major Businesses
Table 116. BOC Sciences Product Features and Attributes
Table 117. BOC Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. BOC Sciences Recent Developments
Table 119. CKTTDB Corporation Information
Table 120. CKTTDB Description and Major Businesses
Table 121. CKTTDB Product Features and Attributes
Table 122. CKTTDB Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. CKTTDB Recent Developments
Table 124. HitGen Corporation Information
Table 125. HitGen Description and Major Businesses
Table 126. HitGen Product Features and Attributes
Table 127. HitGen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. HitGen Recent Developments
Table 129. WuXi AppTec Corporation Information
Table 130. WuXi AppTec Description and Major Businesses
Table 131. WuXi AppTec Product Features and Attributes
Table 132. WuXi AppTec Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. WuXi AppTec Recent Developments
Table 134. LeadBuilder Corporation Information
Table 135. LeadBuilder Description and Major Businesses
Table 136. LeadBuilder Product Features and Attributes
Table 137. LeadBuilder Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. LeadBuilder Recent Developments
Table 139. CSNpharm Corporation Information
Table 140. CSNpharm Description and Major Businesses
Table 141. CSNpharm Product Features and Attributes
Table 142. CSNpharm Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. CSNpharm Recent Developments
Table 144. ChemNavigator Corporation Information
Table 145. ChemNavigator Description and Major Businesses
Table 146. ChemNavigator Product Features and Attributes
Table 147. ChemNavigator Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. ChemNavigator Recent Developments
Table 149. Raw Materials Key Suppliers
Table 150. Distributors List
Table 151. Market Trends and Market Evolution
Table 152. Market Drivers and Opportunities
Table 153. Market Challenges, Risks, and Restraints
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Virtual Screening for Drug Discovery Product Picture
Figure 2. Global Virtual Screening for Drug Discovery Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Structure-based Virtual Screening (SBVS) Product Picture
Figure 4. Ligand-based Virtual Screening (LBVS) Product Picture
Figure 5. Hybrid Methods Product Picture
Figure 6. Global Virtual Screening for Drug Discovery Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Pharmaceutical Company
Figure 8. Universities and Research Institutions
Figure 9. Others
Figure 10. Virtual Screening for Drug Discovery Report Years Considered
Figure 11. Global Virtual Screening for Drug Discovery Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 13. Global Virtual Screening for Drug Discovery Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Virtual Screening for Drug Discovery Revenue Market Share by Region (2020-2031)
Figure 15. Global Virtual Screening for Drug Discovery Revenue Market Share Ranking (2024)
Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 17. Structure-based Virtual Screening (SBVS) Revenue Market Share by Player in 2024
Figure 18. Ligand-based Virtual Screening (LBVS) Revenue Market Share by Player in 2024
Figure 19. Hybrid Methods Revenue Market Share by Player in 2024
Figure 20. Global Virtual Screening for Drug Discovery Revenue Market Share by Type (2020-2031)
Figure 21. Global Virtual Screening for Drug Discovery Revenue Market Share by Application (2020-2031)
Figure 22. North America Virtual Screening for Drug Discovery Revenue YoY (2020-2031) & (US$ Million)
Figure 23. North America Top 5 Players Virtual Screening for Drug Discovery Revenue (US$ Million) in 2024
Figure 24. North America Virtual Screening for Drug Discovery Revenue (US$ Million) by Type (2020 - 2031)
Figure 25. North America Virtual Screening for Drug Discovery Revenue (US$ Million) by Application (2020-2031)
Figure 26. US Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 27. Canada Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 28. Mexico Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 29. Europe Virtual Screening for Drug Discovery Revenue YoY (2020-2031) & (US$ Million)
Figure 30. Europe Top 5 Players Virtual Screening for Drug Discovery Revenue (US$ Million) in 2024
Figure 31. Europe Virtual Screening for Drug Discovery Revenue (US$ Million) by Type (2020-2031)
Figure 32. Europe Virtual Screening for Drug Discovery Revenue (US$ Million) by Application (2020-2031)
Figure 33. Germany Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 34. France Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 35. U.K. Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 36. Italy Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 37. Russia Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Virtual Screening for Drug Discovery Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Top 8 Players Virtual Screening for Drug Discovery Revenue (US$ Million) in 2024
Figure 40. Asia-Pacific Virtual Screening for Drug Discovery Revenue (US$ Million) by Type (2020-2031)
Figure 41. Asia-Pacific Virtual Screening for Drug Discovery Revenue (US$ Million) by Application (2020-2031)
Figure 42. Indonesia Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 43. Japan Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 44. South Korea Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 45. Australia Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 46. India Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 47. Indonesia Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 48. Vietnam Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 49. Malaysia Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 50. Philippines Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 51. Singapore Virtual Screening for Drug Discovery Revenue (2020-2031) & (US$ Million)
Figure 52. Central and South America Virtual Screening for Drug Discovery Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Central and South America Top 5 Players Virtual Screening for Drug Discovery Revenue (US$ Million) in 2024
Figure 54. Central and South America Virtual Screening for Drug Discovery Revenue (US$ Million) by Type (2020-2031)
Figure 55. Central and South America Virtual Screening for Drug Discovery Revenue (US$ Million) by Application (2020-2031)
Figure 56. Brazil Virtual Screening for Drug Discovery Revenue (2020-2025) & (US$ Million)
Figure 57. Argentina Virtual Screening for Drug Discovery Revenue (2020-2025) & (US$ Million)
Figure 58. Middle East and Africa Virtual Screening for Drug Discovery Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Middle East and Africa Top 5 Players Virtual Screening for Drug Discovery Revenue (US$ Million) in 2024
Figure 60. South America Virtual Screening for Drug Discovery Revenue (US$ Million) by Type (2020-2031)
Figure 61. Middle East and Africa Virtual Screening for Drug Discovery Revenue (US$ Million) by Application (2020-2031)
Figure 62. GCC Countries Virtual Screening for Drug Discovery Revenue (2020-2025) & (US$ Million)
Figure 63. Israel Virtual Screening for Drug Discovery Revenue (2020-2025) & (US$ Million)
Figure 64. Egypt Virtual Screening for Drug Discovery Revenue (2020-2025) & (US$ Million)
Figure 65. South Africa Virtual Screening for Drug Discovery Revenue (2020-2025) & (US$ Million)
Figure 66. Virtual Screening for Drug Discovery Industry Chain Mapping
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global Virtual Screening for Drug Discovery market?
The top companies in the global Virtual Screening for Drug Discovery market are MedChemExpress、TargetMol、OpenEye Scientific.
Related Reports
Global Virtual Screening for Drug Discovery Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Virtual Screening for Drug Discovery market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-31
Pages: 160
USD 4900.00
(Single User License)
Global Virtual Screening for Drug Discovery Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Virtual Screening for Drug Discovery market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published Date: 2026-03-31
Pages: 105
USD 4250.00
(Single User License)
Virtual Screening for Drug Discovery - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Virtual Screening for Drug Discovery was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-19
Pages: 139
USD 3950.00
(Single User License)
Global Virtual Screening for Drug Discovery Market Research Report 2026
The global Virtual Screening for Drug Discovery market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-15
Pages: 127
USD 2900.00
(Single User License)
Global Virtual Screening for Drug Discovery Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Virtual Screening for Drug Discovery market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-09-06
Pages: 105
USD 4250.00
(Single User License)
Virtual Screening for Drug Discovery- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Virtual Screening for Drug Discovery was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-03-11
Pages: 121
USD 3950.00
(Single User License)
Global Virtual Screening for Drug Discovery Market Research Report 2025
The global market for Virtual Screening for Drug Discovery was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-03-11
Pages: 99
USD 2900.00
(Single User License)
Global Virtual Screening for Drug Discovery Market Research Report 2024
Virtual screening (VS) is a computational technique used in drug discovery to search libraries of small molecules in order to identify those structures which are most likely to bind to a drug target, typically a protein receptor or enzyme.
Published Date: 2024-04-28
Pages: 95
USD 2900.00
(Single User License)
Virtual Screening for Drug Discovery- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Virtual screening (VS) is a computational technique used in drug discovery to search libraries of small molecules in order to identify those structures which are most likely to bind to a drug target, typically a protein receptor or enzyme.
Published Date: 2024-04-28
Pages: 138
USD 3950.00
(Single User License)
Global and United States Virtual Screening for Drug Discovery Market Report & Forecast 2024-2030
Virtual screening (VS) is a computational technique used in drug discovery to search libraries of small molecules in order to identify those structures which are most likely to bind to a drug target, typically a protein receptor or enzyme.
Published Date: 2024-04-28
Pages: 121
USD 4350.00
(Single User License)
Global Virtual Screening for Drug Discovery Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Virtual Screening for Drug Discovery market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-31
Pages: 160
USD 4900.00 (Single User License)Global Virtual Screening for Drug Discovery Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Virtual Screening for Drug Discovery market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published: 2026-03-31
Pages: 105
USD 4250.00 (Single User License)Virtual Screening for Drug Discovery - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Virtual Screening for Drug Discovery was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-01-19
Pages: 139
USD 3950.00 (Single User License)Global Virtual Screening for Drug Discovery Market Research Report 2026
The global Virtual Screening for Drug Discovery market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-01-15
Pages: 127
USD 2900.00 (Single User License)Global Virtual Screening for Drug Discovery Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Virtual Screening for Drug Discovery market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-09-06
Pages: 105
USD 4250.00 (Single User License)Virtual Screening for Drug Discovery- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Virtual Screening for Drug Discovery was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-03-11
Pages: 121
USD 3950.00 (Single User License)Global Virtual Screening for Drug Discovery Market Research Report 2025
The global market for Virtual Screening for Drug Discovery was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-03-11
Pages: 99
USD 2900.00 (Single User License)Global Virtual Screening for Drug Discovery Market Research Report 2024
Virtual screening (VS) is a computational technique used in drug discovery to search libraries of small molecules in order to identify those structures which are most likely to bind to a drug target, typically a protein receptor or enzyme.
Published: 2024-04-28
Pages: 95
USD 2900.00 (Single User License)Virtual Screening for Drug Discovery- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Virtual screening (VS) is a computational technique used in drug discovery to search libraries of small molecules in order to identify those structures which are most likely to bind to a drug target, typically a protein receptor or enzyme.
Published: 2024-04-28
Pages: 138
USD 3950.00 (Single User License)Global and United States Virtual Screening for Drug Discovery Market Report & Forecast 2024-2030
Virtual screening (VS) is a computational technique used in drug discovery to search libraries of small molecules in order to identify those structures which are most likely to bind to a drug target, typically a protein receptor or enzyme.
Published: 2024-04-28
Pages: 121
USD 4350.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now